本文選題：肺孢子菌肺炎 + 非獲得性免疫缺陷綜合征　； 參考：《中華醫(yī)院感染學(xué)雜志》2014年06期

【摘要】：目的研究非艾滋病(AIDS)免疫功能抑制患者發(fā)生肺孢子菌肺炎(PCP)的臨床特點(diǎn)并對(duì)β-D-葡聚糖的診斷價(jià)值和治療藥物進(jìn)行探討。方法回顧性分析呼吸科2010年7月-2011年6月收治的15例非AIDS免疫功能抑制患者發(fā)生PCP的臨床表現(xiàn)、實(shí)驗(yàn)室檢查、治療及轉(zhuǎn)歸,采用STATA 8.0統(tǒng)計(jì)軟件。結(jié)果所有患者發(fā)生PCP前均接受了激素或免疫抑制劑治療,其中14例應(yīng)用了潑尼松或甲潑尼龍,9例應(yīng)用了嗎替麥考酚酯,15例患者平均APACHEⅡ評(píng)分為(16±5)分,氧合指數(shù)均300mm Hg,66.7%的患者CD4淋巴細(xì)胞計(jì)數(shù)200/μl,93.3%的患者血清β-D-葡聚糖升高;所有患者的抗PCP治療均聯(lián)合應(yīng)用了卡泊芬凈和磺胺甲惡唑/甲氧芐啶,總體病死率26.7%,接受無創(chuàng)通氣或有創(chuàng)機(jī)械通氣患者病死率為50.0%,高于未接受無創(chuàng)通氣或有創(chuàng)機(jī)械通氣患者(P=0.077)。結(jié)論非AIDS免疫功能抑制患者中PCP的病死率較高,β-D-葡聚糖可以做為PCP感染的一個(gè)診斷參考指標(biāo),卡泊芬凈聯(lián)合磺胺甲惡唑/甲氧芐啶治療PCP有效。
[Abstract]:Objective to study the clinical features of PCPP in patients with Pneumocystis pneumocystis pneumonia (PCPP) in patients with non-AIDS AIDS immunosuppression, and to explore the diagnostic value and therapeutic drugs of 尾 -Dglucan. Methods the clinical manifestation, laboratory examination, treatment and outcome of PCP in 15 patients with non AIDS immunosuppression admitted from July 2010 to June 2011 were analyzed retrospectively. STATA 8.0 software was used. Results all patients were treated with hormone or immunosuppressant before PCP, of which 14 received prednisone or methylprednisolone in 9 patients, and the average APACHE 鈪，

本文編號(hào)：1831477